It was announced that the important milestone of obtaining hit compounds had been achieved in joint drug discovery research with TORAY INDUSTRIES,INC. The target is PCSK9 gene mRNA, and the research aims to discover drugs using this new approach targeting its three-dimensional structure.
Veritas In Silico announced that it had achieved the important research milestone of obtaining hit compounds in its joint drug discovery research with TORAY INDUSTRIES,INC. This indicates progress in the research and the potential for future commercialisation.
The target is the three-dimensional structure of PCSK9 gene mRNA itself, and the research aims to discover drugs using a globally novel approach that targets its design information. PCSK9 is produced in the liver and involved in regulating LDL cholesterol in the blood, and the usefulness of a mechanism of action targeting mRNA is expected to be validated.
The global PCSK9 inhibitor market is projected to be worth approximately $14 billion in 2034. The creation of a PCSK9-targeted drug with a novel mechanism of action could provide an opportunity to capture market share. Under the current milestone, the rights to the research and development will be jointly held by TORAY INDUSTRIES,INC. and VIS.
The disclosure was based on a press release dated 19 October, and the progress of future research and development and commercialisation is expected to contribute to an increase in corporate value over the medium to long term.